Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINJECTIONStandard

ERAXIS

ANIDULAFUNGIN

Standard Dose
50MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Prescription
Summary

Approval overview ERAXIS is listed in Drugs@FDA under application 021948 (NDA).

Review priority: PRIORITY Marketing status: Prescription Active ingredient ANIDULAFUNGIN Form and strength INJECTABLE; INJECTION - 50MG Sponsor PFIZER Submission history Latest submission status date: 2006-02-17 00:00:00.

Structured Monograph

Clinical summary

Approval overview ERAXIS is listed in Drugs@FDA under application 021948 (NDA). Review priority: PRIORITY Marketing status: Prescription Active ingredient ANIDULAFUNGIN Form and strength INJECTABLE; INJECTION - 50MG Sponsor PFIZER Submission history Latest submission status date: 2006-02-17 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: PRIORITY

Interaction Notes

  • No interaction notes stored yet.